NCT04035733Phase 2Completed

rVA576 in Adult Mild to Moderate Bullous Pemphigoid Subjects

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Open ClinicalTrials.gov record CSV export · Pro

Primary completion2020-03-12Actual

Enrollment · participants9Actual

Source updated2025-04-22Last update listed in the registry record

Version history

Changes to this trial

Last 12 months

Pro unlocks the full available history and CSV export. View Pro features

No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.

Study details

Conditions studied

Bullous Pemphigoid (BP)

Treatments or interventions studied

rVA576Drug

Primary outcomes · main study measures

Read the study measures

measure: Safety parameter; description: Proportion of participants reporting grade 3, 4 and 5 adverse events, which are related/possibly related to rVA576 during the treatment period. Treatment emergent adverse events (TEAEs) consist of: * Change from baseline in physical examination * ECG * Clinical laboratory tests * Vital signs The Common Terminology Criteria for Adverse Events (CTCAE v4.03) will be used to grade adverse events.; timeFrame: 42 days

History coverage

Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

How to read this history